Media headlines about Agilent Technologies (NYSE:A) have trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agilent Technologies earned a news impact score of 0.24 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.8767636203772 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Agilent Technologies to acquire Advanced Analytical Technologies (financial-news.co.uk)
- Agilent Receives 2018 Scientists’ Choice Awards (it.tmcnet.com)
- Agilent Receives 2018 Scientists’ Choice Awards (finance.yahoo.com)
- Agilent’s AATI Acquisition to Strengthen Portfolio, Footprint – Nasdaq (nasdaq.com)
- Here’s What Short-Term Traders Should Know – Agilent Technologies Inc (NYSE: A) – Alpha Beta Stock (alphabetastock.com)
Agilent Technologies (NYSE:A) traded down $0.43 during midday trading on Monday, reaching $70.71. The company had a trading volume of 2,050,000 shares, compared to its average volume of 2,910,000. The company has a market cap of $22,800.00, a price-to-earnings ratio of 31.57, a PEG ratio of 2.38 and a beta of 1.30. Agilent Technologies has a 1-year low of $51.48 and a 1-year high of $75.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.78 and a current ratio of 3.23.
Several research firms have recently weighed in on A. Robert W. Baird reiterated a “buy” rating and issued a $76.00 price objective on shares of Agilent Technologies in a research note on Thursday, January 18th. JPMorgan Chase & Co. upped their price objective on Agilent Technologies from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Barclays upped their price objective on Agilent Technologies from $67.00 to $71.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Deutsche Bank set a $75.00 price objective on Agilent Technologies and gave the company a “buy” rating in a research note on Tuesday, November 21st. Finally, Cowen reiterated a “hold” rating and issued a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Agilent Technologies presently has a consensus rating of “Buy” and a consensus target price of $70.98.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 43,703 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $70.00, for a total value of $3,059,210.00. Following the transaction, the chief executive officer now directly owns 302,837 shares in the company, valued at approximately $21,198,590. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 21,850 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,638,750.00. Following the completion of the transaction, the chief executive officer now owns 324,687 shares in the company, valued at $24,351,525. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 102,970 shares of company stock worth $7,340,641.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.